<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar1207</article-id><article-id pub-id-type="pmid">15380041</article-id><article-id pub-id-type="doi">10.1186/ar1207</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Estrogen receptor-&#x003b1; gene haplotype is associated with primary knee osteoarthritis in Korean population</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>Jin</surname><given-names>Sheng-Yu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jinsy11@hotmail.com</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Hong</surname><given-names>Seung-Jae</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hsj718@medimail.co.kr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>In Yang</surname><given-names>Hyung</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>yhira@chollian.net</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Park</surname><given-names>Sang-do</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>kanikos@medimail.co.kr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Yoo</surname><given-names>Myung-Chul</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mcyookuh@chol.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Lee</surname><given-names>Hee Jae</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>poohlee@dreamwiz.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Hong</surname><given-names>Mee-Suk</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>msbona21@korea.com</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Park</surname><given-names>Hae-Jeong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>hjpark17@hotmail.com</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Yoon</surname><given-names>Seo Hyun</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ena0512@hotmail.com</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Kim</surname><given-names>Bum-Shik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>kimbs95@hotamil.com</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Yim</surname><given-names>Sung-Vin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ysvin@khu.ac.kr</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Park</surname><given-names>Hun-Kuk</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sigmoidus@khu.ac.kr</email></contrib><contrib id="A13" corresp="yes" contrib-type="author"><name><surname>Chung</surname><given-names>Joo-Ho</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jhchung@khu.ac.kr</email></contrib></contrib-group><aff id="I1"><label>1</label>Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University, Seoul, Korea</aff><aff id="I2"><label>2</label>Department of Internal Medicine, College of Medicine, Pochon CHA University, Sungnam, Korea</aff><aff id="I3"><label>3</label>Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea</aff><aff id="I4"><label>4</label>Department of Orthopedic Surgery, College of Medicine, Kyung Hee University, Seoul, Korea</aff><pub-date pub-type="ppub"><year>2004</year></pub-date><pub-date pub-type="epub"><day>19</day><month>7</month><year>2004</year></pub-date><volume>6</volume><issue>5</issue><fpage>R415</fpage><lpage>R421</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/6/5/R415"/><history><date date-type="received"><day>19</day><month>2</month><year>2004</year></date><date date-type="rev-request"><day>5</day><month>4</month><year>2004</year></date><date date-type="rev-recd"><day>26</day><month>5</month><year>2004</year></date><date date-type="accepted"><day>8</day><month>6</month><year>2004</year></date></history><copyright-statement>Copyright &#x000a9; 2004 Jin et al.; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><abstract><p>Estrogen and estrogen receptors (ERs) are known to play important roles in the pathophysiology of osteoarthritis (OA). To investigate ER-&#x003b1; gene polymorphisms for its associations with primary knee OA, we conducted a case&#x02013;control association study in patients with primary knee OA (<italic>n </italic>= 151) and healthy individuals (<italic>n </italic>= 397) in the Korean population. Haplotyping analysis was used to determine the relationship between three polymorphisms in the ER-&#x003b1; gene (intron 1 T/C, intron 1 A/G and exon 8 G/A) and primary knee OA. Genotypes of the ER-&#x003b1; gene polymorphism were determined by PCR followed by restriction enzyme digestion (<italic>Pvu</italic>II for intron 1 T/C, <italic>Xba</italic>I for intron 1 A/G, and <italic>Btg</italic>I for exon 8 G/A polymorphism). There was no significant difference between primary knee OA patients and healthy control individuals in the distribution of any of the genotypes evaluated. However, we found that the allele frequency for the exon 8 G/A <italic>Btg</italic>I polymorphism (codon 594) was significantly different between primary knee OA patients and control individuals (odds ratio = 1.38, 95% confidence interval = 1.01&#x02013;1.88; <italic>P = </italic>0.044). In haplotype frequency estimation analysis, there was a significant difference between primary knee OA patients and control individuals (degrees of freedom = 7, &#x003c7;<sup>2 </sup>= 21.48; <italic>P </italic>= 0.003). Although the number OA patients studied is small, the present study shows that ER-&#x003b1; gene haplotype may be associated with primary knee OA, and genetic variations in the ER-&#x003b1; gene may be involved in OA.</p></abstract><kwd-group><kwd>estrogen receptor</kwd><kwd>haplotype</kwd><kwd>knee osteoarthritis</kwd><kwd>polymorphism</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Osteoarthritis (OA) is a common disorder among the elderly. It is multifactorial disorder, with predisposing factors included advanced age, and genetic, hormonal and mechanical factors [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Furthermore, recent studies have revealed a role for the inflammatory process in the pathogenesis of OA [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. It has been reported that the development of OA may be influenced by multiple genes [<xref ref-type="bibr" rid="B6">6</xref>]. A number of candidate genes have been suggested to mediate susceptibility to OA, including collagen genes (<italic>COL1A1</italic>, <italic>COL2A1</italic>, <italic>COL9A1</italic>, <italic>COL11A2</italic>), and the genes encoding cartilage matrix protein 1 (<italic>CMP1</italic>), vitamin D receptor (<italic>VDR</italic>), insulin-like growth factor-1 (<italic>IGF1</italic>), transforming growth factor-&#x003b2;<sub>1 </sub>(<italic>TGF&#x003b2;1</italic>), aggrecan-1 (<italic>AGC1</italic>), tissue inhibitor of metalloproteinase 3 (<italic>TIMP3</italic>), interleukin-1 receptor (<italic>IL1R</italic>), and the estrogen receptor [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The human estrogen receptor (ER) has two isoforms: ER-&#x003b1; and ER-&#x003b2;. The former isoform is a ligand-activated transcription factor composed of several important domains for hormone binding, DNA binding, and activation of transcription [<xref ref-type="bibr" rid="B7">7</xref>]. ER-&#x003b1; is an important mediator in the signal transduction pathway [<xref ref-type="bibr" rid="B7">7</xref>]. The ER is a member of the steroid/thyroid hormone superfamily of nuclear receptors [<xref ref-type="bibr" rid="B8">8</xref>]. The ER-&#x003b1; gene is greater than 140 kilobases, contains eight exons, and is located on chromosome 6q25 [<xref ref-type="bibr" rid="B9">9</xref>]. The coding region has a length of 1785 nucleotides, and it is translated into a protein of 595 amino acids and 66 kDa [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Several variations in the DNA sequence of the ER-&#x003b1; gene have been reported [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. A few reports have examined the association between ER-&#x003b1; gene polymorphisms and OA; the findings are controversial. Ushiyama and co-workers [<xref ref-type="bibr" rid="B13">13</xref>] reported associations between a genotype of <italic>Pvu</italic>II and <italic>Xba</italic>I polymorphisms in intron 1 of the ER-&#x003b1; gene and generalized OA. Bergink and co-workers [<xref ref-type="bibr" rid="B14">14</xref>] found that an ER-&#x003b1; haplotype of <italic>Pvu</italic>II and <italic>Xba</italic>I polymorphisms was associated with radiographic OA of the knee. However, Loughlin and co-workers [<xref ref-type="bibr" rid="B15">15</xref>] found no association between ER-&#x003b1; gene polymorphisms and idiopathic OA. Some studies of <italic>Btg</italic>I polymorphisms have been conducted in other diseases. Cancel-Tassin and co-workers [<xref ref-type="bibr" rid="B16">16</xref>] reported that a <italic>Btg</italic>I (594 A/G) polymorphism was not associated with risk for prostate cancer. Tanaka and colleagues [<xref ref-type="bibr" rid="B17">17</xref>] reported similar findings in prostate cancer patients. In another study, the <italic>Btg</italic>I (594 A/G) polymorphism was not associated with renal cell carcinoma [<xref ref-type="bibr" rid="B18">18</xref>]. Curran and co-workers [<xref ref-type="bibr" rid="B19">19</xref>] reported an association of A/G polymorphism in exon 8 of the ER gene with sporadic breast cancer. However, no findings regarding the relationship between exon 8 A/G polymorphism and OA have been reported.</p><p>In the present study, we first analyzed the association between the exon 8 G/A <italic>Btg</italic>I polymorphism (database-single nucleotide polymorphism number rs2228480; codon 594) of the ER-&#x003b1; gene and primary knee OA in patients from the Korean population. We also investigated the association between haplotypes of three polymorphisms (<italic>Pvu</italic>II in intron 1, <italic>Xba</italic>I in intron 1, and <italic>Btg</italic>I in exon 8) and primary knee OA.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study subjects</title><p>A total of 151 patients with primary knee OA (98 women and 53 men) from the Korean population were included in the study. Patients were examined at the Rheumatology Clinic in Kyung Hee University Medical Center, Seoul, Korea. In total, 397 control individuals (207 women and 190 men) underwent the 2003 health examination. OA was diagnosed according to American College of Rheumatology criteria, which include primary OA with any symptom and/or sign of OA, positive finding on radiographs according to the Kellgren-Lawrence grading [<xref ref-type="bibr" rid="B20">20</xref>], and no evidence of arthritis due to other disease. The study was approved by the ethics review committee of the Medical Research Institute, Kyung Hee University Medical Center, Seoul, Korea.</p><p>Clinical information and classification of primary knee osteoarthritisThe age at onset of OA is important clinically because it is associated with long-term prognosis. During the study, we were able to identify the current age and age at onset of disease in the 151 knee OA patients by individual interview conducted at our outpatient clinic. The current age of OA patients (mean &#x000b1; standard deviation) was 58.8 &#x000b1; 9.6 years, and the age at onset of OA was 52.0 &#x000b1; 9.5 years. We therefore stratified clinical data according to mean onset age of disease: older or younger than 52.0 years. The group with disease onset at age &#x0003c;52.0 years was defined as the 'early' onset, and the group of disease onset at age &#x0003e;52.0 years was defined as the 'late' onset group.</p><p>The Kellgren-Lawrence grade represents disease severity, as reflected on radiographs, and Lequesne's functional index represents functional or symptomatic status of patients [<xref ref-type="bibr" rid="B21">21</xref>]. Radiographic findings of OA were classified into mild (Kellgren-Lawrence grade 1 or 2) or severe (Kellgren-Lawrence grade 3 or 4). The functional or symptomatic status of OA patients was classified as functionally or symptomatically good (Lequesne's functional index = 10) or poor (Lequesne's functional index &#x0003e; 10; Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Analysis of estrogen receptor-&#x003b1; gene polymorphisms</title><p>Genomic DNA was prepared from whole blood samples using the NucleoSpin DNA isolation kit (Macherey-Nagel GmbH &#x00026; Co., D&#x000fc;ren, Germany). PCR amplifications were performed using 50 ng genomic DNA in a 30 &#x003bc;l reaction volume containing 0.5 &#x003bc;l 10 pmol sense primer, 0.5 &#x003bc;l 10 pmol antisense primer, 0.5 &#x003bc;l 2.5 mmol/l dNTP (Takra, Shiga, Japan), 1 U Taq DNA polymerase (Neurotics Inc., Seoul, Korea), and in buffer containing 25 mmol/l MgCl<sub>2</sub>, 750 mmol/l Tris-HCl (pH 9.0), 150 mmol/l ammonium sulfate, and 1 mg/ml bovine serum albumin. Samples were subjected to 35 cycles of amplification in GeneAmp PCR system 2700 (Applied Biosystems, Foster, CA, USA). PCR primers used in the study are listed in Table <xref ref-type="table" rid="T2">2</xref>[<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. The PCR products were digested under the conditions specified by the enzyme supplier (New England Biolabs Inc, Beverly, MA, USA). Restriction fragments were separated by agarose gel electrophoresis and ethidium bromide staining.</p></sec><sec><title>Statistical analysis</title><p>For the case&#x02013;control association study, the significance of differences in allelic and genotypic frequencies between OA patients and control populations was determined using standard &#x003c7;<sup>2 </sup>tests. We used the EH program [<xref ref-type="bibr" rid="B23">23</xref>] to investigate the relative risks associated with haplotypes. <italic>P </italic>&#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec><title>Results</title><sec><title>Distribution of estrogen receptor-&#x003b1; genotypes in osteoarthritis patients and control individuals</title><p>As shown in Table <xref ref-type="table" rid="T3">3</xref>, three single nucleotide polymorphisms were identified in ER-&#x003b1; intron 1 (T/C, A/G) and exon 8 (G/A). When the allele frequency of the exon 8 G/A <italic>Btg</italic>I polymorphism was compared between OA patients and control individuals, a significant difference was observed (odds ratio [OR] = 1.38, 95% confidence interval [CI] = 1.01&#x02013;1.88; <italic>P </italic>= 0.044). However, the genotype distribution did not exhibit a significant difference between OA patients and control individuals (<italic>P </italic>= 0.13). Observed genotype and allele frequencies for the intron 1 T/C <italic>Pvu</italic>II and the intron 1 A/G <italic>Xba</italic>I polymorphisms were not significantly different between OA patients and control individuals (Table <xref ref-type="table" rid="T3">3</xref>). There was no evidence of deviation from Hardy-Weinberg equilibrium in healthy control individuals (for intron 1 T/C <italic>Pvu</italic>II polymorphism, <italic>P </italic>= 0.85; for intron 1 A/G <italic>Xba</italic>I polymorphism, <italic>P </italic>= 0.99; and for exon 8 G/A <italic>Btg</italic>I polymorphism, <italic>P </italic>= 0.77).</p></sec><sec><title>Estrogen receptor-&#x003b1; gene polymorphisms and sex of osteoarthritis patients</title><p>As shown in Table <xref ref-type="table" rid="T4">4</xref>, the observed genotype distribution (<italic>P </italic>= 0.04) and allele frequency (OR = 1.89, 95% CI = 1.15&#x02013;3.11; <italic>P </italic>= 0.01) for the exon 8 G/A <italic>Btg</italic>I polymorphism were significantly different between male OA patients and male control individuals, whereas those in females exhibited no significant difference. We compared genptype distributions and allele frequencies for the intron 1 T/C <italic>Pvu</italic>II and the intron 1 A/G <italic>Xba</italic>I polymorphisms. There were no significant differences in the polymorphisms between OA patients and controls of the same sex.</p></sec><sec><title>Estrogen receptor-&#x003b1; gene polymorphisms and risk for late onset osteoarthritis</title><p>Late onset OA patients were defined as those with disease onset at age above 52 years, whereas early onset OA patients had their disease onset at age under 52 years. When comparing allele frequency of the exon 8 G/A <italic>Btg</italic>I polymorphism between late onset OA patients and control individuals, a significant difference was observed (OR = 1.62, 95% CI = 1.07&#x02013;2.46; <italic>P </italic>= 0.021). However, the genotype distribution did not exhibit a significant difference between OA patients and control individuals (<italic>P </italic>= 0.06). The genotype distributions and allele frequencies of the intron 1 T/C <italic>Pvu</italic>II and the intron 1 A/G <italic>Xba</italic>I polymorphisms were not significantly different between late onset OA patients and control individuals. When comparing genotype distributions and allele frequencies of the intron 1 T/C <italic>Pvu</italic>II, the intron 1 A/G <italic>Xba</italic>I, and the exon 8 G/A <italic>Btg</italic>I polymorphisms between early onset OA patients and control individuals, no significant difference was observed (Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>Estrogen receptor-&#x003b1; gene polymorphisms and risk for radiographically severe osteoarthritis</title><p>Patients with radiographically severe OA were defined as those whose Kellgren-Lawrence grade was 3 or 4, whereas radiographically mild OA was defined as Kellgren-Lawrence grade 1 or 2. When comparing genotype distributions and allele frequencies of the intron 1 T/C <italic>Pvu</italic>II, the intron 1 A/G <italic>Xba</italic>I, and the exon 8 G/A <italic>Btg</italic>I polymorphisms between patients with mild OA and control individuals, no significant difference was observed (Table <xref ref-type="table" rid="T4">4</xref>). The genotype distributions and allele frequencies of the intron 1 T/C <italic>Pvu</italic>II, the intron 1 A/G <italic>Xba</italic>I, and the exon 8 G/A <italic>Btg</italic>I polymorphisms did not exhibit significant differences between patients with severe OA and control individuals (Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>Estrogen receptor-&#x003b1; gene polymorphisms and risk for functionally poor osteoarthritis</title><p>OA patients who were functionally or symptomatically poor (poor index) were defined as those who with a Lequesne's functional index score over 10, whereas those who were functionally or symptomatically good (good index) had a Lequesne's functional index score less than or equal to 10. Genotype distributions and allele frequencies of the intron 1 T/C <italic>Pvu</italic>II, the intron 1 A/G <italic>Xba</italic>I, and the exon 8 G/A <italic>Btg</italic>I polymorphisms between OA patients with a good and those with a poor index, and control individuals were not significantly different (Table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>Estrogen receptor-&#x003b1; haplotype analysis in patients with primary knee osteoarthritis</title><p>Table <xref ref-type="table" rid="T5">5</xref> shows the frequency of each haplotype. The difference was significant between all OA patients combined and control individuals (degrees of freedom [df] = 7, &#x003c7;<sup>2 </sup>= 21.48; <italic>P </italic>= 0.003). There was no significant difference between female patients and female control individuals (df = 7, &#x003c7;<sup>2 </sup>= 8.22; <italic>P </italic>= 0.31). However, there was a significant difference between male OA patients and male control individuals (df = 7, &#x003c7;<sup>2 </sup>= 16.76; <italic>P </italic>= 0.019; Table <xref ref-type="table" rid="T5">5</xref>).</p><p>The late onset, radiographically severe, and poor index subgroups of OA patients exhibited significant differences in haplotype distribution (Table <xref ref-type="table" rid="T6">6</xref>). There was a significant difference between patients with late onset OA and control individuals (df = 7, &#x003c7;<sup>2 </sup>= 21.96; <italic>P </italic>= 0.002) but not between patients with early onset OA and control individuals (df = 7, &#x003c7;<sup>2 </sup>= 7.42; <italic>P </italic>= 0.390). When comparing patients with radiographically severe OA and control individuals, a significant difference was observed (df = 7, &#x003c7;<sup>2 </sup>= 23.96; <italic>P </italic>= 0.001), but this was not the case in patients with radiographically mild OA (df = 7, &#x003c7;<sup>2 </sup>= 13.60; <italic>P </italic>= 0.059). There was a significant difference between OA patients with a poor index and control individuals (df = 7, &#x003c7;<sup>2 </sup>= 14.66; <italic>P </italic>= 0.041), but this was not the case for OA patients with a good index (df = 7, &#x003c7;<sup>2 </sup>= 10.96; <italic>P </italic>= 0.140; Table <xref ref-type="table" rid="T6">6</xref>).</p></sec></sec><sec><title>Discussion</title><p>We report here, for the first time, on the associations of exon 8 G/A <italic>Btg</italic>I polymorphism (codon 594) in the ER-&#x003b1; gene and ER-&#x003b1; haplotypes of three polymorphisms (<italic>Pvu</italic>II in intron 1, <italic>Xba</italic>I in intron 1, and <italic>Btg</italic>I in exon 8) with primary knee OA in the Korean population. Several reports [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>] have indicated that estrogen and its receptor might be involved in the etiology of OA. Until now three reports on the relationship between ER-&#x003b1; polymorphisms and OA had been published. Two studies [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>] reported that a ER-&#x003b1; polymorphism was associated with OA. Ushiyama and co-workers [<xref ref-type="bibr" rid="B13">13</xref>] found an association between a genotype of <italic>Pvu</italic>II and <italic>Xba</italic>I polymorphisms in intron 1 and generalized OA with severe radiographic changes in the Japanese population (65 OA patients and 318 control individuals). In a population-based study conducted in a Caucasian population (1483 subjects), Bergink and co-workers [<xref ref-type="bibr" rid="B14">14</xref>] reported that ER-&#x003b1; haplotype of <italic>Pvu</italic>II and <italic>Xba</italic>I polymorphisms was associated with radiographic OA of the knee. One study showed no relationship between ER-&#x003b1; gene polymorphisms and OA in a Caucasian population (371 OA patients and 369 control individuals) [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Our study showed that the genotype distributions for the intron 1 T/C <italic>Pvu</italic>II and the intron 1 A/G <italic>Xba</italic>I polymorphisms were not associated with OA, a finding similar to that reported by Loughlin and co-workers [<xref ref-type="bibr" rid="B15">15</xref>]. However, the allele frequency for the <italic>Btg</italic>I polymorphism was significantly different between OA and control individuals. The difference in the allele frequency was more marked in OA patients with late onset of disease and in male patients (Table <xref ref-type="table" rid="T4">4</xref>). The haplotype of three polymorphisms was associated with OA. We conducted further analysis of OA patients subdivided by clinical parameters and found that the haplotype exhibited a strong association with late onset, radiographically severe, and functionally poor OA of the knee, and in particular with male sex (Tables <xref ref-type="table" rid="T5">5</xref> and <xref ref-type="table" rid="T6">6</xref>). However, the TAA and CAG haplotypes exhibited differences between female and male control individuals (Table <xref ref-type="table" rid="T5">5</xref>). Haplotype TAA had frequencies of 0.12 and 0.05 in female and male control individuals, but its frequencies in male and female OA patients were 0.18 and 0.14, respectively. Haplotype CAG had a frequency of 0.18 in female control individuals, 0.18 in female patients and 0.18 in male patients, but its frequency in the male control individuals was 0.31. This discrepancy may be due to the small numbers of male control individuals (<italic>n </italic>= 190) and male OA patients (<italic>n </italic>= 53).</p><p>The genotype distribution of the <italic>Pvu</italic>II and <italic>Xba</italic>I polymorphisms in the ER-&#x003b1; gene was reported to differ between racial and ethnic groups [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. In the present study, genotype and allele frequencies in control individuals were similar to previously reported distributions in the Chinese population [<xref ref-type="bibr" rid="B27">27</xref>]. Interestingly, the exon 8 G/A <italic>Btg</italic>I polymorphism and haplotype of three polymorphisms (<italic>Pvu</italic>II in intron 1, <italic>Xba</italic>I in intron 1, and <italic>Btg</italic>I in exon 8) were associated with OA in men but not in women.</p><p>Our sample size was relatively small and our data were subjected to a number of uncorrected tests, and therefore our positive results may represent false-positive findings. To confirm the association between ER-&#x003b1; polymorphisms and OA, additional studies are required.</p></sec><sec><title>Conclusion</title><p>In conclusion, we found that ER-&#x003b1; gene haplotype may be associated with primary knee OA in the Korean population, and that genetic variations in the ER-&#x003b1; gene might play a role in susceptibility to OA.</p></sec><sec><title>Competing interests</title><p>None declared.</p></sec><sec><title>Abbreviations</title><p>CI = confidence interval; df = degrees of freedom; ER = estrogen receptor; OA = osteoarthritis; OR = odds ratio; PCR = polymerase chain reaction.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by an Oriental Medicine Research Center for Bone and Joint Disease grant from the Ministry of Health and Welfare of the Republic of Korea (03-PJ9-PG6-SO01-0002).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Cheras</surname><given-names>PA</given-names></name></person-group><article-title>Vascular mechanisms in osteoarthritis</article-title><source>Best Pract Res Clin Rheumatol</source><year>2001</year><volume>15</volume><fpage>693</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">11812016</pub-id><pub-id pub-id-type="doi">10.1053/berh.2001.0188</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reginato</surname><given-names>AM</given-names></name><name><surname>Olsen</surname><given-names>BR</given-names></name></person-group><article-title>The role of structural genes in the pathogenesis of osteoarthritic disorders</article-title><source>Arthritis Res</source><year>2002</year><volume>4</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">12453309</pub-id><pub-id pub-id-type="doi">10.1186/ar595</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Johanne</surname><given-names>MP</given-names></name><name><surname>Abramson</surname><given-names>SB</given-names></name></person-group><article-title>Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets</article-title><source>Arthritis Rheum</source><year>2001</year><volume>44</volume><fpage>1237</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">11407681</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200106)44:6&#x0003c;1237::AID-ART214&#x0003e;3.0.CO;2-F</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>GH</given-names></name><name><surname>Kayo</surname><given-names>MH</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name></person-group><article-title>Immunologic intervention in the pathogenesis of osteoarthritis</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">12632410</pub-id><pub-id pub-id-type="doi">10.1002/art.10768</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandell</surname><given-names>LJ</given-names></name><name><surname>Aigner</surname><given-names>T</given-names></name></person-group><article-title>Articular cartilage and changes in arthritis. An introduction: cell biology of osteoarthritis</article-title><source>Arthritis Res</source><year>2001</year><volume>3</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">11178118</pub-id><pub-id pub-id-type="doi">10.1186/ar148</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aigner</surname><given-names>T</given-names></name><name><surname>Dudhia</surname><given-names>J</given-names></name></person-group><article-title>Genomics of osteoarthritis</article-title><source>Curr Opin Rheumatol</source><year>2003</year><volume>15</volume><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">12960493</pub-id><pub-id pub-id-type="doi">10.1097/00002281-200309000-00019</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shupnik</surname><given-names>MA</given-names></name><name><surname>Pitt</surname><given-names>LK</given-names></name><name><surname>Soh</surname><given-names>AY</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Lopes</surname><given-names>MB</given-names></name><name><surname>Laws</surname><given-names>ER</given-names><suffix>Jr</suffix></name></person-group><article-title>Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>3965</fpage><lpage>3972</lpage><pub-id pub-id-type="pmid">9814476</pub-id><pub-id pub-id-type="doi">10.1210/jc.83.11.3965</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RM</given-names></name></person-group><article-title>The steroid and thyroid hormone receptor superfamily</article-title><source>Science</source><year>1988</year><volume>240</volume><fpage>889</fpage><lpage>895</lpage><pub-id pub-id-type="pmid">3283939</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menasce</surname><given-names>LP</given-names></name><name><surname>White</surname><given-names>GR</given-names></name><name><surname>Harrison</surname><given-names>CJ</given-names></name><name><surname>Boyle</surname><given-names>JM</given-names></name></person-group><article-title>Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique</article-title><source>Genomics</source><year>1993</year><volume>17</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">8406468</pub-id><pub-id pub-id-type="doi">10.1006/geno.1993.1320</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>S</given-names></name><name><surname>Walter</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Krust</surname><given-names>A</given-names></name><name><surname>Bornert</surname><given-names>JM</given-names></name><name><surname>Argos</surname><given-names>P</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><article-title>Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A</article-title><source>Nature</source><year>1986</year><volume>320</volume><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">3754034</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>EL</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Newman</surname><given-names>B</given-names></name><name><surname>King</surname><given-names>KC</given-names></name></person-group><article-title>Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility</article-title><source>J Steroid Biochem Mol Biol</source><year>1999</year><volume>71</volume><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10619354</pub-id><pub-id pub-id-type="doi">10.1016/S0960-0760(99)00126-0</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Sakuragi</surname><given-names>N</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Six polymorphisms on estrogen receptor 1 gene in Japanese, American and German populations</article-title><source>Eur J Clin Pharmacol</source><year>2003</year><volume>59</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">12923601</pub-id><pub-id pub-id-type="doi">10.1007/s00228-003-0609-z</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ushiyama</surname><given-names>T</given-names></name><name><surname>Ueyama</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Nishioka</surname><given-names>J</given-names></name><name><surname>Ohkubo</surname><given-names>I</given-names></name><name><surname>Hukuda</surname><given-names>S</given-names></name></person-group><article-title>Estrogen receptor gene polymorphism and generalized osteoarthritis</article-title><source>J Rheumatol</source><year>1998</year><volume>25</volume><fpage>134</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">9458216</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergink</surname><given-names>AP</given-names></name><name><surname>van Meurs</surname><given-names>JB</given-names></name><name><surname>Loughlin</surname><given-names>J</given-names></name><name><surname>Arp</surname><given-names>PP</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>van Leeuwen</surname><given-names>JP</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>Pols</surname><given-names>HA</given-names></name></person-group><article-title>Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>1913</fpage><lpage>1922</lpage><pub-id pub-id-type="pmid">12847685</pub-id><pub-id pub-id-type="doi">10.1002/art.11046</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loughlin</surname><given-names>J</given-names></name><name><surname>Sinsheimer</surname><given-names>JS</given-names></name><name><surname>Mustafa</surname><given-names>Z</given-names></name><name><surname>Carr</surname><given-names>AJ</given-names></name><name><surname>Clipsham</surname><given-names>K</given-names></name><name><surname>Bloomfield</surname><given-names>VA</given-names></name><name><surname>Chitnavis</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>A</given-names></name><name><surname>Sykes</surname><given-names>B</given-names></name><name><surname>Chapman</surname><given-names>K</given-names></name></person-group><article-title>Association analysis of the vitamin D receptor gene, the type I collagen gene COL1A1, and the estrogen receptor gene in idiopathic osteoarthritis</article-title><source>J Rheumatol</source><year>2000</year><volume>27</volume><fpage>779</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">10743824</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cancel-Tassin</surname><given-names>G</given-names></name><name><surname>Latil</surname><given-names>A</given-names></name><name><surname>Rousseau</surname><given-names>F</given-names></name><name><surname>Mangin</surname><given-names>P</given-names></name><name><surname>Bottius</surname><given-names>E</given-names></name><name><surname>Escary</surname><given-names>JL</given-names></name><name><surname>Berthon</surname><given-names>P</given-names></name><name><surname>Cussenot</surname><given-names>O</given-names></name></person-group><article-title>Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk</article-title><source>Eur Urol</source><year>2003</year><volume>44</volume><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="pmid">14499686</pub-id><pub-id pub-id-type="doi">10.1016/S0302-2838(03)00319-1</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kaneuchi</surname><given-names>M</given-names></name><name><surname>Shiina</surname><given-names>H</given-names></name><name><surname>Igawa</surname><given-names>M</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Polymorphisms of estrogen receptor alpha in prostate cancer</article-title><source>Mol Carcinog</source><year>2003</year><volume>37</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">12891629</pub-id><pub-id pub-id-type="doi">10.1002/mc.10138</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Kaneuchi</surname><given-names>M</given-names></name><name><surname>Fujimoto</surname><given-names>S</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Single nucleotide polymorphisms of estrogen receptor a in human renal cell carcinoma</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>296</volume><fpage>1200</fpage><lpage>1206</lpage><pub-id pub-id-type="pmid">12207901</pub-id><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02045-4</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>JE</given-names></name><name><surname>Lea</surname><given-names>RA</given-names></name><name><surname>Rutherford</surname><given-names>S</given-names></name><name><surname>Weinstein</surname><given-names>SR</given-names></name><name><surname>Griffiths</surname><given-names>LR</given-names></name></person-group><article-title>Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer</article-title><source>Int J Cancer</source><year>2001</year><volume>95</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">11400122</pub-id><pub-id pub-id-type="doi">10.1002/1097-0215(20010720)95:4&#x0003c;271::AID-IJC1046&#x0003e;3.0.CO;2-D</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kellgren</surname><given-names>JK</given-names></name><name><surname>Lawrence</surname><given-names>JS</given-names></name></person-group><article-title>Radiological assessment of osteoarthritis</article-title><source>Ann Rheum Dis</source><year>1957</year><volume>16</volume><fpage>494</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">13498604</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lequesne</surname><given-names>M</given-names></name><name><surname>M&#x000e9;ry</surname><given-names>C</given-names></name><name><surname>Samson</surname><given-names>M</given-names></name><name><surname>G&#x000e9;rard</surname><given-names>P</given-names></name></person-group><article-title>Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests</article-title><source>Scand J Rheumatol</source><year>1987</year><volume>Suppl 65</volume><fpage>85</fpage><lpage>89</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Hong</surname><given-names>CJ</given-names></name><name><surname>Chiu</surname><given-names>HJ</given-names></name></person-group><article-title>Association study of oestrogen receptor alpha gene polymorphism and suicidal behaviours in major depressive disorder</article-title><source>Psychiatr Genet</source><year>2003</year><volume>13</volume><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12605096</pub-id><pub-id pub-id-type="doi">10.1097/00041444-200303000-00003</pub-id></citation></ref><ref id="B23"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Terwilliger</surname><given-names>JD</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Linkage disequilibrium between alleles at marker loci</article-title><source>In Handbook of Human Genetic Linkage</source><year>1994</year><edition>1</edition><publisher-name>Baltimore: Johns Hopkins University</publisher-name><fpage>188</fpage><lpage>198</lpage></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ushiyama</surname><given-names>T</given-names></name><name><surname>Ueyama</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><name><surname>Ohkubo</surname><given-names>I</given-names></name><name><surname>Hukuda</surname><given-names>S</given-names></name></person-group><article-title>Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes</article-title><source>Osteoarthritis Cartilage</source><year>1999</year><volume>7</volume><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">10558854</pub-id><pub-id pub-id-type="doi">10.1053/joca.1999.0260</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>CL</given-names></name><name><surname>Liu</surname><given-names>TK</given-names></name><name><surname>Chen</surname><given-names>TJ</given-names></name></person-group><article-title>Estrogen and osteoarthritis: a study of synovial estradiol and estradiol receptor binding in human osteoarthritic knees</article-title><source>Biochem Biophys Res Commun</source><year>1992</year><volume>183</volume><fpage>1287</fpage><lpage>1291</lpage><pub-id pub-id-type="pmid">1567405</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Campion</surname><given-names>GD</given-names></name></person-group><article-title>Generalized osteoarthritis: a hormonally mediated disease</article-title><source>Ann Rheum Dis</source><year>1989</year><volume>48</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">2662920</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Wen</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>JR</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>Genetic polymorphisms in the estrogen receptor &#x003b1; gene and risk of breast cancer: results from the Shanghai Breast cancer study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2003</year><volume>12</volume><fpage>853</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">14504194</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of the patients with primary knee osteoarthritis patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Characteristic</td><td align="left">Findings</td></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">58.8 &#x000b1; 9.6</td></tr><tr><td align="left">Number women/men (<italic>n</italic>)</td><td align="left">98/53</td></tr><tr><td align="left">Age at onset age (years)</td><td align="left">52.0 &#x000b1; 9.5</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">25.2 &#x000b1; 2.9</td></tr><tr><td align="left">Duration of osteoarthritis (years)</td><td align="left">6.8 &#x000b1; 5.9</td></tr><tr><td align="left">Kellgren-Lawrence grade (<italic>n</italic>): 1/2/3/4</td><td align="left">6/84/56/5</td></tr><tr><td align="left">Lequesne's index</td><td align="left">10.2 &#x000b1; 2.5</td></tr></tbody></table><table-wrap-foot><p>A total of 151 patients with primary knee osteoarthritis were included. Values are expressed as mean &#x000b1; standard deviation or as numbers.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Sequences of primers used for estrogen receptor-&#x003b1; genotyping</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphism site</td><td align="left">Primer sets</td><td align="left">Annealing temperature (&#x000b0;C)</td><td align="left">Restriction enzyme</td><td align="left">Allele size (bp)</td></tr></thead><tbody><tr><td align="left">Intron 1 T/C</td><td align="left">5'-ctgccaccctatctgtatcttttcctattctcc-3'<break/>5'-tctttctctgccaccctggcgtcgattatctga-3'</td><td align="left">64</td><td align="left"><italic>Pvu</italic>II</td><td align="left">T: 936 + 438<break/>C: 1374</td></tr><tr><td align="left">Intron 1 A/G</td><td align="left">5'-ctgccaccctatctgtatcttttcctattctcc-3'<break/>5'-tctttctctgccaccctggcgtcgattatctga-3'</td><td align="left">64</td><td align="left"><italic>Xba</italic>I</td><td align="left">A: 981 + 393<break/>G: 1374</td></tr><tr><td align="left">Exon 8 G/A</td><td align="left">5'-gaggagacggaccaaagccac-3'<break/>5'-gccattggtgttggatgcatg-3'</td><td align="left">63</td><td align="left"><italic>Btg</italic>I</td><td align="left">G: 129 + 98<break/>A: 227</td></tr></tbody></table><table-wrap-foot><p>bp, base pairs.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Genotype distribution and allele frequency of estrogen receptor-&#x003b1; gene polymorphisms in patients with osteoarthritis and control individuals</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center">Groups</td><td align="center" colspan="4">ER-&#x003b1; genotypes</td><td align="center" colspan="5">ER-&#x003b1; alleles</td></tr><tr><td></td><td colspan="4"><hr></hr></td><td colspan="5"><hr></hr></td></tr><tr><td></td><td></td><td align="center">OA (%)</td><td align="center">Control (%)</td><td align="center"><italic>P</italic><sup>a</sup></td><td></td><td align="center">OA (%)</td><td align="center">Control (%)</td><td align="center"><italic>P</italic><sup>b</sup></td><td align="center">OR (95% CI)</td></tr><tr><td colspan="5"><hr></hr></td><td colspan="5"><hr></hr></td></tr><tr><td align="center"><italic>Pvu</italic>II (T/C)</td><td align="center">TT</td><td align="center">61 (40.4)</td><td align="center">152 (38.3)</td><td align="center">0.89</td><td align="center">T</td><td align="center">190 (62.9)</td><td align="center">487 (61.3)</td><td align="center">0.63</td><td align="center">0.93 (0.71&#x02013;1.23)</td></tr><tr><td></td><td align="center">CT</td><td align="center">68 (45.0)</td><td align="center">183 (46.1)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">CC</td><td align="center">22 (14.6)</td><td align="center">62 (15.6)</td><td></td><td align="center">C</td><td align="center">112 (37.1)</td><td align="center">307 (38.7)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center"><italic>Xba</italic>I (A/G)</td><td align="center">AA</td><td align="center">98 (64.9)</td><td align="center">256 (64.5)</td><td align="center">0.81</td><td align="center">A</td><td align="center">245 (81.1)</td><td align="center">638 (80.3)</td><td align="center">0.77</td><td align="center">0.95 (0.68&#x02013;1.33)</td></tr><tr><td></td><td align="center">AG</td><td align="center">49 (32.4)</td><td align="center">126 (31.7)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">GG</td><td align="center">4 (2.70)</td><td align="center">15 (3.80)</td><td></td><td align="center">G</td><td align="center">57 (18.9)</td><td align="center">156 (19.7)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center"><italic>Btg</italic>I (G/A)</td><td align="center">GG</td><td align="center">84 (55.6)</td><td align="center">257 (64.7)</td><td align="center">0.13</td><td align="center">G</td><td align="center">225 (74.5)</td><td align="center">636 (80.1)</td><td align="center">0.044</td><td align="center">1.38 (1.01&#x02013;1.88)</td></tr><tr><td></td><td align="center">GA</td><td align="center">57 (37.8)</td><td align="center">122 (30.7)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">AA</td><td align="center">10 (6.60)</td><td align="center">18 (4.60)</td><td></td><td align="center">A</td><td align="center">77 (25.5)</td><td align="center">158 (19.9)</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>A total of 151 patients with osteoarthritis (OA) and 397 control individuals were included in the study. <sup>a</sup>Control individuals versus patients using the &#x003c7;<sup>2 </sup>test with 3 &#x000d7; 2 contingency table. <sup>b</sup>Control individuals versus patients using the &#x003c7;<sup>2 </sup>test with 2 &#x000d7; 2 contingency table. CI, confidence interval; ER, estrogen receptor; OR, odds ratio.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Comparison of estrogen receptor-&#x003b1; gene polymorphisms in subtypes of osteoarthritis patients and control individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Clinical subtypes</td><td align="center" colspan="9">Genotype distributions<sup>a</sup></td><td align="center" colspan="6">Allele frequencies<sup>b</sup></td></tr><tr><td></td><td colspan="9"><hr></hr></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center" colspan="4"><italic>Pvu</italic>II</td><td align="center" colspan="3"><italic>Xba</italic>I</td><td align="center" colspan="3"><italic>Btg</italic>I</td><td align="center" colspan="2"><italic>Pvu</italic>II</td><td align="center" colspan="2"><italic>Xba</italic>I</td><td align="center" colspan="2"><italic>Btg</italic>I</td></tr><tr><td></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="center">TT</td><td align="center">TC</td><td align="center">CC</td><td align="center">AA</td><td align="center">AG</td><td align="center">GG</td><td align="center">GG</td><td align="center">GA</td><td align="center">AA</td><td align="center">T</td><td align="center">C</td><td align="center">A</td><td align="center">G</td><td align="center">G</td><td align="center">A</td></tr></thead><tbody><tr><td align="center">Women (<italic>n </italic>= 98)</td><td align="center">43 (43.9)</td><td align="center">42 (42.8)</td><td align="center">13 (13.3)</td><td align="center">64 (65.3)</td><td align="center">33 (33.7)</td><td align="center">1 (1.00)</td><td align="center">57 (58.2)</td><td align="center">35 (35.7)</td><td align="center">6 (6.10)</td><td align="center">128 (65.3)</td><td align="center">68 (34.7)</td><td align="center">161 (82.1)</td><td align="center">35 (17.9)</td><td align="center">149 (76.0)</td><td align="center">47 (24.0)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 3.84; <italic>P </italic>= 0.15</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.05; <italic>P </italic>= 0.59</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.23; <italic>P </italic>= 0.89</td><td align="center" colspan="2">1.15 (0.80&#x02013;1.64); <italic>P </italic>= 0.45</td><td align="center" colspan="2">0.91 (0.58&#x02013;1.41); <italic>P </italic>= 0.67</td><td align="center" colspan="2">1.10 (0.74&#x02013;1.65); <italic>P </italic>= 0.63</td></tr><tr><td align="center">Men <break/>(<italic>n </italic>= 53)</td><td align="center">18 (34.0)</td><td align="center">26 (49.0)</td><td align="center">9 (17.0)</td><td align="center">34 (64.1)</td><td align="center">16 (30.2)</td><td align="center">3 (5.70)</td><td align="center">27 (75.5)</td><td align="center">22 (20.7)</td><td align="center">4 (3.80)</td><td align="center">62 (58.5)</td><td align="center">44 (41.5)</td><td align="center">84 (79.2)</td><td align="center">22 (20.8)</td><td align="center">76 (71.78)</td><td align="center">30 (28.3)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.69; <italic>P </italic>= 0.43</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.07; <italic>P </italic>= 0.96</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 6.28; <italic>P </italic>= 0.043</td><td align="center" colspan="2">0.82 (0.53&#x02013;1.27); <italic>P </italic>= 0.38</td><td align="center" colspan="2">1.04 (0.62&#x02013;1.78); <italic>P </italic>= 0.86</td><td align="center" colspan="2">1.89 (1.15&#x02013;3.11); <italic>P </italic>= 0.011</td></tr><tr><td align="center">Early onset<sup>c </sup>(<italic>n </italic>= 85)</td><td align="center">34 (40.0)</td><td align="center">41 (48.2)</td><td align="center">10 (11.8)</td><td align="center">52 (61.2)</td><td align="center">31 (36.5)</td><td align="center">2 (2.30)</td><td align="center">51 (60.0)</td><td align="center">29 (34.1)</td><td align="center">5 (5.90)</td><td align="center">109 (64.1)</td><td align="center">61 (35.9)</td><td align="center">135 (79.4)</td><td align="center">35 (20.6)</td><td align="center">131 (77.1)</td><td align="center">39 (22.9)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.82; <italic>P </italic>= 0.66</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.00; <italic>P </italic>= 0.60</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.77; <italic>P </italic>= 0.68</td><td align="center" colspan="2">0.893 (0.63&#x02013;1.25); <italic>P </italic>= 0.50</td><td align="center" colspan="2">1.06 (0.70&#x02013;1.60); <italic>P </italic>= 0.78</td><td align="center" colspan="2">1.20 (0.80&#x02013;1.78); <italic>P </italic>= 0.37</td></tr><tr><td align="center">Late onset<sup>c </sup>(<italic>n </italic>= 66)</td><td align="center">27 (40.9)</td><td align="center">27 (40.9)</td><td align="center">12 (18.2)</td><td align="center">46 (69.7)</td><td align="center">18 (27.3)</td><td align="center">2 (3.00)</td><td align="center">33 (50.0)</td><td align="center">28 (42.4)</td><td align="center">5 (7.60)</td><td align="center">81 (61.4)</td><td align="center">51 (38.6)</td><td align="center">110 (83.3)</td><td align="center">22 (16.7)</td><td align="center">94 (71.2)</td><td align="center">38 (28.8)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.67; <italic>P </italic>= 0.71</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.68; <italic>P </italic>= 0.71</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 5.40; <italic>P </italic>= 0.07</td><td align="center" colspan="2">1.00 (0.68&#x02013;1.46); <italic>P </italic>= 0.99</td><td align="center" colspan="2">1.82 (0.50&#x02013;1.33); <italic>P </italic>= 0.42</td><td align="center" colspan="2">1.63 (1.07&#x02013;2.46); <italic>P </italic>= 0.021</td></tr><tr><td align="center">Mild<sup>d</sup><italic>(n </italic>= 90)</td><td align="center">44 (48.9)</td><td align="center">33 (36.7)</td><td align="center">13 (14.4)</td><td align="center">67 (74.5)</td><td align="center">21 (23.3)</td><td align="center">2 (2.20)</td><td align="center">50 (55.6)</td><td align="center">33 (36.76)</td><td align="center">7 (7.80)</td><td align="center">121 (67.2)</td><td align="center">59 (32.8)</td><td align="center">155 (86.1)</td><td align="center">25 (13.9)</td><td align="center">133 (73.9)</td><td align="center">47 (26.1)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 3.58; <italic>P </italic>= 0.17</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 3.32; <italic>P </italic>= 0.19</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.30; <italic>P </italic>= 0.19</td><td align="center" colspan="2">0.77 (0.55&#x02013;1.09); <italic>P </italic>= 0.14</td><td align="center" colspan="2">0.66 (0.42&#x02013;1.04); <italic>P </italic>= 0.07</td><td align="center" colspan="2">1.42 (0.98&#x02013;2.07); <italic>P </italic>= 0.06</td></tr><tr><td align="center">Severe<sup>d </sup>(<italic>n </italic>= 61)</td><td align="center">17 (27.9)</td><td align="center">35 (57.4)</td><td align="center">9 (14.7)</td><td align="center">31 (50.8)</td><td align="center">28 (45.9)</td><td align="center">2 (3.30)</td><td align="center">34 (55.7)</td><td align="center">24 (39.3)</td><td align="center">3 (4.90)</td><td align="center">69 (56.6)</td><td align="center">53 (43.4)</td><td align="center">90 (73.8)</td><td align="center">32 (26.2)</td><td align="center">92 (75.4)</td><td align="center">30 (24.6)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 2.99; <italic>P </italic>= 0.22</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 4.76; <italic>P </italic>= 0.09</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.92; <italic>P </italic>= 0.38</td><td align="center" colspan="2">1.22 (0.83&#x02013;1.79); <italic>P </italic>= 0.31</td><td align="center" colspan="2">1.45 (0.94&#x02013;2.26); <italic>P </italic>= 0.09</td><td align="center" colspan="2">1.31 (0.84&#x02013;2.05); <italic>P </italic>= 0.23</td></tr><tr><td align="center">Good index<sup>e </sup>(<italic>n </italic>= 82)</td><td align="center">32 (39.0)</td><td align="center">35 (42.7)</td><td align="center">15 (18.3)</td><td align="center">52 (63.4)</td><td align="center">28 (34.2)</td><td align="center">2 (2.40)</td><td align="center">45 (54.9)</td><td align="center">31 (37.8)</td><td align="center">6 (7.30)</td><td align="center">99 (60.4)</td><td align="center">65 (39.6)</td><td align="center">132 (80.5)</td><td align="center">32 (19.5)</td><td align="center">121 (73.8)</td><td align="center">43 (26.2)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.68; <italic>P </italic>= 0.78</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.48; <italic>P </italic>= 0.78</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 3.16; <italic>P </italic>= 0.21</td><td align="center" colspan="2">1.04 (0.74&#x02013;1.47); <italic>P </italic>= 0.82</td><td align="center" colspan="2">0.99 (0.65&#x02013;1.51); <italic>P </italic>= 0.97</td><td align="center" colspan="2">1.43 (0.97&#x02013;2.11); <italic>P </italic>= 0.07</td></tr><tr><td align="center">Poor index<sup>e </sup>(<italic>n </italic>= 69)</td><td align="center">29 (42.0)</td><td align="center">33 (47.8)</td><td align="center">7 (10.2)</td><td align="center">46 (66.7)</td><td align="center">21 (30.4)</td><td align="center">2 (2.90)</td><td align="center">39 (56.5)</td><td align="center">26 (37.7)</td><td align="center">4 (5.80)</td><td align="center">91 (65.9)</td><td align="center">47 (34.1)</td><td align="center">113 (81.9)</td><td align="center">25 (18.1)</td><td align="center">104 (75.4)</td><td align="center">34 (24.6)</td></tr><tr><td></td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.44; <italic>P </italic>= 0.49</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 0.20; <italic>P </italic>= 0.90</td><td align="center" colspan="3">&#x003c7;<sup>2 </sup>= 1.72; <italic>P </italic>= 0.42</td><td align="center" colspan="2">0.82 (0.56&#x02013;1.20); <italic>P </italic>= 0.30</td><td align="center" colspan="2">0.90 (0.57&#x02013;1.44); <italic>P </italic>= 0.67</td><td align="center" colspan="2">1.32 (0.86&#x02013;2.01); <italic>P </italic>= 0.20</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Control versus patients using the &#x003c7;<sup>2 </sup>test with 3 &#x000d7; 2 contingency table. <sup>b</sup>Control versus patients using the &#x003c7;<sup>2 </sup>test with 2 &#x000d7; 2 contingency table. <sup>c</sup>Early onset osteoarthritis OA patients were defined as those with disease onset at age under 52 years, whereas late onset OA patients were those with onset at age over 52 years. <sup>d</sup>Based on radiographic findings, OA patients were classified into mild (Kellgren-Lawrence grade 1 or 2) or severe (Kellgren-Lawrence grade 3 or 4). <sup>e</sup>Based on Lequesne's functional index score, poor OA patients were defined as those with an index score over 10, whereas good OA patients had an index score less than or equal to 10.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Comparison of estrogen receptor-&#x003b1; gene haplotypes in osteoarthritis patients and control individuals</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Haplotype</td><td align="center" colspan="3">Controls</td><td align="center" colspan="3">OA patients</td></tr><tr><td></td><td colspan="3"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center">Total</td><td align="center">Women</td><td align="center">Men</td><td align="center">Total</td><td align="center">Women</td><td align="center">Men</td></tr><tr><td colspan="4"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td align="left">TAG</td><td align="center">0.41</td><td align="center">0.44</td><td align="center">0.37</td><td align="center">0.41</td><td align="center">0.42</td><td align="center">0.40</td></tr><tr><td align="left">TAA</td><td align="center">0.09</td><td align="center">0.12</td><td align="center">0.05</td><td align="center">0.17</td><td align="center">0.18</td><td align="center">0.14</td></tr><tr><td align="left">TGG</td><td align="center">0.09</td><td align="center">0.09</td><td align="center">0.08</td><td align="center">0.05</td><td align="center">0.05</td><td align="center">0.05</td></tr><tr><td align="left">TGA</td><td align="center">0.03</td><td align="center">0.03</td><td align="center">0.02</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td></tr><tr><td align="left">CAG</td><td align="center">0.25</td><td align="center">0.18</td><td align="center">0.31</td><td align="center">0.18</td><td align="center">0.18</td><td align="center">0.18</td></tr><tr><td align="left">CAA</td><td align="center">0.06</td><td align="center">0.06</td><td align="center">0.06</td><td align="center">0.05</td><td align="center">0.04</td><td align="center">0.07</td></tr><tr><td align="left">CGG</td><td align="center">0.06</td><td align="center">0.06</td><td align="center">0.08</td><td align="center">0.10</td><td align="center">0.10</td><td align="center">0.09</td></tr><tr><td align="left">CGA</td><td align="center">0.02</td><td align="center">0.01</td><td align="center">0.02</td><td align="center">0.04</td><td align="center">0.02</td><td align="center">0.07</td></tr><tr><td></td><td></td><td></td><td></td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 21.48; <italic>P</italic><sup>a </sup>= 0.003</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 8.22; <italic>P</italic><sup>a </sup>= 0.314</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 16.76; <italic>P</italic><sup>a </sup>= 0.019</td></tr></tbody></table><table-wrap-foot><p>A total of 397 control individuals and 151 osteoarthritis (OA) patients were included in the study. Values given are haplotype frequencies. <sup>a</sup><italic>P </italic>values for overall difference in haplotype distribution between OA patients and control individuals were calculated using the EH program [23]. df, degrees of freedom.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Comparison of estrogen receptor-&#x003b1; gene haplotypes in subtypes of osteoarthritis patients and control individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Haplotypes</td><td align="center">Control</td><td align="center">Early onset<sup>a</sup></td><td align="center">Late onset<sup>a</sup></td><td align="center">Mild<sup>b</sup></td><td align="center">Severe<sup>b</sup></td><td align="center">Good<sup>c</sup></td><td align="center">Poor<sup>c</sup></td></tr></thead><tbody><tr><td align="left">TAG</td><td align="center">0.41</td><td align="center">0.41</td><td align="center">0.41</td><td align="center">0.43</td><td align="center">0.39</td><td align="center">0.39</td><td align="center">0.44</td></tr><tr><td align="left">TAA</td><td align="center">0.09</td><td align="center">0.16</td><td align="center">0.18</td><td align="center">0.18</td><td align="center">0.15</td><td align="center">0.16</td><td align="center">0.17</td></tr><tr><td align="left">TGG</td><td align="center">0.09</td><td align="center">0.07</td><td align="center">0.02</td><td align="center">0.06</td><td align="center">0.02</td><td align="center">0.05</td><td align="center">0.05</td></tr><tr><td align="left">TGA</td><td align="center">0.03</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td><td align="center">&#x0003c;0.01</td></tr><tr><td align="left">CAG</td><td align="center">0.25</td><td align="center">0.19</td><td align="center">0.17</td><td align="center">0.19</td><td align="center">0.16</td><td align="center">0.19</td><td align="center">0.17</td></tr><tr><td align="left">CAA</td><td align="center">0.06</td><td align="center">0.04</td><td align="center">0.07</td><td align="center">0.06</td><td align="center">0.04</td><td align="center">0.06</td><td align="center">0.04</td></tr><tr><td align="left">CGG</td><td align="center">0.06</td><td align="center">0.10</td><td align="center">0.11</td><td align="center">0.05</td><td align="center">0.18</td><td align="center">0.11</td><td align="center">0.10</td></tr><tr><td align="left">CGA</td><td align="center">0.02</td><td align="center">0.04</td><td align="center">0.04</td><td align="center">0.02</td><td align="center">0.06</td><td align="center">0.04</td><td align="center">0.03</td></tr><tr><td></td><td></td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 7.42; <italic>P</italic><sup>d </sup>= 0.390</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 21.96; <italic>P</italic><sup>d </sup>= 0.002</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 13.60; <italic>P</italic><sup>d </sup>= 0.059</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 23.96; <italic>P</italic><sup>d </sup>= 0.001</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 10.96; <italic>P</italic><sup>d </sup>= 0.14</td><td align="center">df = 7, &#x003c7;<sup>2 </sup>= 14.66; <italic>P</italic><sup>d </sup>= 0.041</td></tr></tbody></table><table-wrap-foot><p>Values given are haplotype frequencies. <sup>a</sup>The mean age at onset in the osteoarthritis (OA) patients was 52.0 years, and so early onset OA patients were defined as those with disease onset at age under 52 years, whereas late onset OA patients were those with onset at age over 52 years. <sup>b</sup>Based on radiographic findings, OA patients were classified as mild (Kellgren-Lawrence grade 1 or 2) or severe (Kellgren-Lawrence grade 3 or 4). <sup>c</sup>Based on Lequesne's functional index score, poor OA patients were defined as those with an index score over 10, whereas good OA patients were those with an index score less than or equal to 10. <sup>d</sup><italic>P </italic>values for overall difference in haplotype distribution between OA patients and control individuals were calculated using the EH program [23]. df, degrees of freedom.</p></table-wrap-foot></table-wrap></sec></back></article> 